ОЦЕНКА ЗАМЕСТИТЕЛЬНОЙ ГОРМОНАЛЬНОЙ ТЕРАПИИ В ЛЕЧЕНИИ ПОСТОПЕРАЦИОННОГО ГИПОПАРАТИРЕОЗА НА ОСНОВЕ КЛИНИЧЕСКИХ РЕКОМЕНДАЦИЙ

Зубайда Халбаева

ассистент кафедры эндокринологии, Самаркандский государственный медицинский университет, Самарканд, Республика Узбекистан

---

Abstract

Постоперационный гипопаратиреоз (ПОГПТ) является одним из наиболее частых осложнений после хирургических вмешательств на щитовидной и паращитовидных железах, приводящим к нарушению кальциевого обмена, гипокальциемии и потенциально тяжелым клиническим проявлениям, таким как тетания, судороги и сердечные аритмии. В статье проводится всесторонняя оценка заместительной гормональной терапии (ЗГТ) на основе современных клинических рекомендаций, включая guidelines от European Society of Endocrinology (ESE, обновленные в 2025 году), Endocrine Society и American Thyroid Association. Анализ охватывает традиционные подходы с использованием солей кальция и активных форм витамина D (кальцитриол, альфакальцидол), а также инновационные методы с применением рекомбинантного паратиреоидного гормона (rhPTH, такие как натипара или терпаратид).

---

References

1. Bollerslev, J., Rejnmark, L., Marcocci, C., Shoback, D. M., Sitges-Serra, A., van Biesen, W., & Dekkers, O. M. (2015). European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. European Journal of Endocrinology, 173(2), G1–G20. https://doi.org/10.1530/EJE-15-0628

2. Brandi, M. L., Bilezikian, J. P., Shoback, D., Bouillon, R., Clarke, B. L., Thakker, R. V., Khan, A. A., & Potts, J. T. (2016). Management of hypoparathyroidism: Summary statement and guidelines. Journal of Clinical Endocrinology & Metabolism, 101(6), 2273–2283. https://doi.org/10.1210/jc.2015-3907

3. Cusano, N. E., Rubin, M. R., McMahon, D. J., Irani, D., Tulley, A., Sliney, J., & Bilezikian, J. P. (2013). Therapy of hypoparathyroidism with PTH(1-84): A prospective four-year investigation of efficacy and safety. Journal of Clinical Endocrinology & Metabolism, 98(1), 137–144. https://doi.org/10.1210/jc.2012-2984

4. Bilezikian, J. P., Khan, A., Potts, J. T., Brandi, M. L., Clarke, B. L., Shoback, D., Jüppner, H., D'Amour, P., Fox, J., Rejnmark, L., Mosekilde, L., Rubin, M. R., Dempster, D., Gafni, R., Collins, M. T., Sliney, J., & Sanders, J. (2016). Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. Journal of Bone and Mineral Research, 31(12), 2317–2337. https://doi.org/10.1002/jbmr.2978

5. Mannstadt, M., Bilezikian, J. P., Thakker, R. V., Hannan, F. M., Clarke, B. L., Rejnmark, L., Mitchell, D. M., Vokes, T. J., Winer, K. K., & Shoback, D. M. (2017). Hypoparathyroidism. Nature Reviews Disease Primers, 3, 17055. https://doi.org/10.1038/nrdp.2017.55

6. Shoback, D. M., Bilezikian, J. P., Costa, A. G., Shaikh, S., Cusano, N. E., Khan, A. A., Liu, J. M., Skrinar, A., & Hu, J. (2016). Presentation of hypoparathyroidism: Etiologies and clinical features. Journal of Clinical Endocrinology & Metabolism, 101(6), 2300–2312. https://doi.org/10.1210/jc.2015-3909

7. Winer, K. K., Ko, C. W., Reynolds, J. C., Dowdy, K., Keil, M., Peterson, D., Gerber, L. H., McGarvey, C., & Cutler, G. B. (2003). Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. Journal of Clinical Endocrinology & Metabolism, 88(9), 4214–4220. https://doi.org/10.1210/jc.2002-021736

8. Underbjerg, L., Sikjaer, T., Mosekilde, L., & Rejnmark, L. (2013). Cardiovascular and renal complications to postsurgical hypoparathyroidism: A Danish nationwide controlled historic follow-up study. Journal of Bone and Mineral Research, 28(11), 2277–2285. https://doi.org/10.1002/jbmr.1979

9. Cusano, N. E., Rubin, M. R., Sliney, J., & Bilezikian, J. P. (2015). Mini-review: New therapeutic options for hypoparathyroidism. Endocrine, 49(3), 566–575. https://doi.org/10.1007/s12020-015-0606-6

10. Orloff, L. A., Wiseman, S. M., Bernet, V. J., Fahey, T. J., Shaha, A. R., Shindo, M. L., Snyder, S. K., Stack, B. C., Sunwoo, J. B., & Wang, M. B. (2018). American Thyroid Association statement on postoperative hypoparathyroidism: Diagnosis, prevention, and management in adults. Thyroid, 28(7), 830–841. https://doi.org/10.1089/thy.2017.0309

11. Khan, A. A., Koch, C. A., Van Uum, S., Baillargeon, J. P., Bollerslev, J., Brandi, M. L., Marcocci, C., Rejnmark, L., Rizzoli, R., Shrayyef, M. Z., Thawer, A., Yildiz, F., & Guyatt, G. (2019). Standards of care for hypoparathyroidism in adults: A Canadian and International Consensus. European Journal of Endocrinology, 180(3), P1–P19. https://doi.org/10.1530/EJE-18-0609

12. Bollerslev, J., Schalin-Jäntti, C., Rejnmark, L., Siggelkow, H., Morreau, H., Thakker, R., Sitges-Serra, A., Cetani, F., Cusano, N., Bartalena, L., Marcocci, C., Khan, A., Brandi, M. L., & Clarke, B. L. (2022). Evaluation and Management of Hypoparathyroidism Summary Statement. Journal of Bone and Mineral Research, 37(12), 2568–2585. https://doi.org/10.1002/jbmr.4691

13. Mannstadt, M., Clarke, B. L., Vokes, T., Brandi, M. L., Rude, R. K., Lakatos, P., Smith, A., McMahon, D. J., Yates, A. J., Papapoulos, S., Klaushofer, K., & Bilezikian, J. P. (2013). Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): A double-blind, placebo-controlled, randomised, phase 3 study. The Lancet Diabetes & Endocrinology, 1(4), 275–283. https://doi.org/10.1016/S2213-8587(13)70106-2

14. Clarke, B. L., Vokes, T. J., Bilezikian, J. P., Shoback, D. M., Lagast, H., & Mannstadt, M. (2016). Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE study results. Journal of Bone and Mineral Research, 32(1), 67–76. https://doi.org/10.1002/jbmr.2962

15. Khan, A. A., Rejnmark, L., Rubin, M., Schwarz, P., Vokes, T., Clarke, B., Hofbauer, L., Marcocci, C., Palermo, A., Mourya, S., Levine, M. A., Schneider, R., Povaley, S., Rao, S. D., Gagle, R., Piccolo, R., O'Meara, M. J., Kiel, S., ... & Bilezikian, J. P. (2023). Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway Trial. Journal of Bone and Mineral Research, 38(4), 433–443. https://doi.org/10.1002/jbmr.4771

16. Melikyan, A. A., & Menkov, A. V. (2020). Postoperative hypoparathyroidism: Prognosis, prevention, and treatment (Review). Sovrem Tekhnologii Med, 12(2), 101–108. https://doi.org/10.17691/stm2020.12.2.13

17. Clarke, B. L. (2022). Hypoparathyroidism: Update of guidelines from the 2022 International Task Force. Arquivos Brasileiros de Endocrinologia & Metabologia, 66(5), 604–610. https://doi.org/10.20945/2359-3997000000549

18. Kannan, T., Foster, Y., Ho, D. J., Gelzinnis, S. J., Merakis, M., Wynne, K., Balogh, Z. J., & Bendinelli, C. (2021). Post-Operative Permanent Hypoparathyroidism and Preoperative Vitamin D Prophylaxis. Journal of Clinical Medicine, 10(3), 442. https://doi.org/10.3390/jcm10030442

19. Tsourdi, E., Amrein, K., Meier, C., Ketteler, M., Kreissl, M. C., Mathew, A., Vogelmann, T., Schubert, T., & Siggelkow, H. (2025). Consensus-Based Recommendations for the Diagnosis, Treatment, and Monitoring of Hypoparathyroidism: Insights from the DACH Region. Calcified Tissue International, 116(1), 1–7. https://doi.org/10.1007/s00223-025-01414-5

20. Rejnmark, L. (2024). Treatment of hypoparathyroidism by re-establishing the effects of parathyroid hormone. Endocrinology and Metabolism, 39(2), 262–266. https://doi.org/10.3803/EnM.2024.1916

21. Khan, A. A., Bilezikian, J. P., Brandi, M. L., Clarke, B. L., Gittoes, N. J., Pasieka, J. L., Rejnmark, L., Shoback, D. M., Potts, J. T., Guyatt, G. H., & Mannstadt, M. (2022). Evaluation and management of hypoparathyroidism: Summary statement and guidelines from the Second International Workshop. Journal of Bone and Mineral Research, 37(12), 2568–2585. https://doi.org/10.1002/jbmr.4691

22. Misiorowski, W., Dedecjus, M., Konstantynowicz, J., Zygmunt, A., Kos-Kudła, B., Lewiński, A., Ruchała, M., & Zgliczyński, W. (2023). Management of hypoparathyroidism: A position statement of the Expert Group of the Polish Society of Endocrinology. Endokrynologia Polska, 74(5), 447–467. https://doi.org/10.5603/ep.96950

23. Maeda, S. S., Moreira, C. A., Borba, V. Z. C., Bandeira, F., Farias, M. L. F. de, Borges, J. L. C., de Paula, F. J. A., Vanderlei, F. A. B., Montenegro, F. L. M. M., Santos, R. O., Ferraz-de-Souza, B., & Lazaretti-Castro, M. (2018). Diagnosis and treatment of hypoparathyroidism: A position statement from the Brazilia Society of Endocrinology and Metabolism. Archives of Endocrinology and Metabolism, 62(1), 106–122. https://doi.org/10.20945/2359-3997000000026